Your browser doesn't support javascript.
loading
Low Prevalence of Interferon α Autoantibodies in People Experiencing Symptoms of Post-Coronavirus Disease 2019 (COVID-19) Conditions, or Long COVID.
Peluso, Michael J; Mitchell, Anthea; Wang, Chung Yu; Takahashi, Saki; Hoh, Rebecca; Tai, Viva; Durstenfeld, Matthew S; Hsue, Priscilla Y; Kelly, J Daniel; Martin, Jeffrey N; Wilson, Michael R; Greenhouse, Bryan; Deeks, Steven G; DeRisi, Joseph L; Henrich, Timothy J.
  • Peluso MJ; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, California, USA.
  • Mitchell A; Chan Zuckerberg Biohub, San Francisco, California, USA.
  • Wang CY; Chan Zuckerberg Biohub, San Francisco, California, USA.
  • Takahashi S; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, California, USA.
  • Hoh R; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, California, USA.
  • Tai V; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, California, USA.
  • Durstenfeld MS; Division of Cardiology, University of California, San Francisco, California, USA.
  • Hsue PY; Division of Cardiology, University of California, San Francisco, California, USA.
  • Kelly JD; Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
  • Martin JN; Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
  • Wilson MR; Department of Neurology, University of California, San Francisco, California, USA.
  • Greenhouse B; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, California, USA.
  • Deeks SG; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, California, USA.
  • DeRisi JL; Chan Zuckerberg Biohub, San Francisco, California, USA.
  • Henrich TJ; Division of Experimental Medicine, University of California, San Francisco, California, USA.
J Infect Dis ; 227(2): 246-250, 2023 01 11.
Article en En | MEDLINE | ID: mdl-36089700
ABSTRACT
Interferon (IFN)-specific autoantibodies have been implicated in severe coronavirus disease 2019 (COVID-19) and have been proposed as a potential driver of the persistent symptoms characterizing "long COVID," a type of postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We report that only 2 of 215 participants with convalescent SARS-CoV-2 infection tested over 394 time points, including 121 people experiencing long COVID symptoms, had detectable IFN-α2 antibodies. Both had been hospitalized during the acute phase of the infection. These data suggest that persistent anti-IFN antibodies, although a potential driver of severe COVID-19, are unlikely to contribute to long COVID symptoms in the postacute phase of the infection.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Diagnostic_studies / Prevalence_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Diagnostic_studies / Prevalence_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article